In 1975 Dr. Roger Wyburn-Mason astounded the medical world with his announcement that he had found two genus of protozoa, Naegleria and Acanthamoeba, as the cause of rheumatoid arthritis and some other diseases. New and profitable fields for medical and laboratory research have been opened as a result of his discoveries. Although full confirmation of his original premise has as yet not been confirmed by clinical pathologists, a new study is now in progress to determine the nature and roles of these amoebae. This is funded by the Rheumatoid Disease Foundation of the United States of America. At the present time no less than 161 physicians and medical centers in 9 countries are engaged in treating patients with the anti-protozoal drugs and are accumulating useful clinical data for the management of the rheumatoid diseases, following a standard protocol.

While the “ideal drug” has not been found there are several antiprotozoal agents which are so effective as to deserve formal clinical trials. A comparison of the preliminary results with some of these substances is the subject of this paper. Therapeutic information and recommendations are being kept current and are exchanged through the Medical and Scientific Advisory Board of the Foundation. This data is available to any physician who may obtain it by writing to the international headquarters.

The acceptance of the probable protozoal etiology of collagen and “auto immune diseases” should not be difficult for the critical rheumatologist.

Every medical practitioner who treats these conditions recognizes that a choice of medicines is necessary and will produce improvement and a high percentage of remissions, without serious side effects or complications. A second research project is under way to select such a drug by in vitro studies and in vivo studies, both sponsored by the Rheumatoid Disease Foundation.

Many investigators have long believed that the rheumatoid diseases were infectious in origin. This was reviewed in 1960 in the textbook edited by Hollander. Fortunately, it is no longer necessary to quote the frequent saying, “There is no known cause and no known cure for rheumatoid arthritis”.

Dr. Wyburn-Mason, as a result of his many years of well documented clinical studies concluded that all of the clinical criteria of an infectious disease are manifested in some stage and form in the acute or chronic forms of rheumatoid disease.

In his 480 page monograph, published only in Japan, he makes the following conclusions:
1. Collagen and auto-immune diseases (the rheumatoid diseases) are all various manifestations of one systemic disease.
2. Successful treatment causes the RF and ANF and various tissue antibodies to disappear.
3. The rheumatoid diseases appear to be infections.
4. Free living (limax) amoebae have been isolated from all causes of these diseases examined.
5. Many substances, known to be amoebaestatic or amoebaecidal to limax amoebae, may rapidly and completely relieve all manifestations or local or generalized rheumatoid disease.
6. And to fulfill all of Koch’s postulates as to the causation of collagen-auto-immune disease, injections of free living amoebae into the tissues of animals result in tissue lesions closely resembling those of rheumatoid disease -- even though the same organisms cannot be distinguished in the tissues.
7. The causative organisms must differ antigenically with strain or species and must contain antigens specific to certain body tissues to produce such a wide range of antibodies, or none at all in certain instances.
8. Most significant is the finding that while a wide range of antiprotozoal drugs are effective in rapidly relieving most cases of rheumatoid disease, in a small proportion of patients there will be a recurrence or no beneficial effect. This would indicate differences in susceptibility and resistance of various strains and manifestations of the amoebae.

Because no virus or bacterial sources have been identified as the etiological agents, and even because these illnesses produce profound disturbances in the immune systems, this is sparse evidence for the “autoimmune” theory. The “Infection theory” of rheumatoid diseases has a much broader base of pathological findings and an almost inexhaustible number of protozoa, mycoplasmas and other microscopic agents for investigation and possible identification of the amoebae.

The therapeutic use of anti-protozoal drugs is a natural forward step for physicians treating arthritis. The antimalarial agents -- which have some antiprotozoal activity -- have been accepted by many physicians and medical centers as a new but successful method of treating rheumatoid disease. The reasons for the effectiveness of these widely differing chemical substances cannot be explained without accepting that some types of infections, probably with protozoa or biologically related organisms, are the cause of this family of illnesses.

The inflammatory natures of rheumatoid diseases have been medically accepted for more than 90 years. But since no single infectious agent has been positively identified, various other etiologies have been accused, including allergies, lack of certain hormones, viruses, bacteria, metabolic defects and the equally unproven “auto-immune” theory.

Evidence on the therapeutic aspect is more tangible. Quinine and quinacrine, long known for their anti-malarial effect, were used in the 1930’s and 1940’s with some success. Chloroquine phosphate, which inhibits protozoal activity and acts similar to gold salts, is still a standard therapeutic agent with many physicians. Looking for a heavy metal similar to gold, copper sulphate and Cuprimyl, a synthetic organic compound including the hydroxyquinoline radical, have produced beneficial results in some patients. Bile salts, which may be the body’s natural protection from pathogenic amoebae in the intestinal tract, have been administered with clinical benefit to persons with rheumatoid diseases by Hench, the Nobel Prize winner for his discovery of cortisone. All of these substances have been demonstrated to be anti-protozoal in laboratory tests.
A Comparison of the Effectiveness of Anti-malarials and the Antiprotozoal Drugs in the Treatment of Rheumatoid Arthritis

<table>
<thead>
<tr>
<th>Drugs</th>
<th>Number of Patients</th>
<th>Improved +</th>
<th>Remissions</th>
<th>% Improved plus Remissions*</th>
<th>Not Improved</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-malarials</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chloroquine</td>
<td>40</td>
<td>26</td>
<td>1</td>
<td>67</td>
<td>6</td>
</tr>
<tr>
<td>Dihydroxyquinine</td>
<td>256</td>
<td>165</td>
<td>25</td>
<td>74</td>
<td>66</td>
</tr>
<tr>
<td>Quinacrine</td>
<td>61</td>
<td>22</td>
<td>14</td>
<td>59</td>
<td>25</td>
</tr>
<tr>
<td>Anti-protozoal</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clotrimazole</td>
<td>9</td>
<td>2</td>
<td>5</td>
<td>77</td>
<td>2</td>
</tr>
<tr>
<td>Metronidazole</td>
<td>462</td>
<td>312</td>
<td>67</td>
<td>82</td>
<td>83</td>
</tr>
<tr>
<td>Tinidazole</td>
<td>14</td>
<td>8</td>
<td>4</td>
<td>85</td>
<td>2</td>
</tr>
</tbody>
</table>

*Percentage Totals of “improved” patients plus “remissions.”

Data from three clinics now using anti-protozoal medications as of April 15, 1985.

ROBERT BINGHAM, M.D., F.A.C.S.

Graduate of the University of Redlands, CA, A.B., 1932. Graduate of the School of Medicine, University of Colorado, M.D., 1938. Internship, Hospital of the University of Pennsylvania, 1940. Orthopaedic Residencies: New York Orthopaedic Hospital and Dispensary and Columbia-Presbyterian Hospital, 1942.


Assistant Clinical Professor of Orthopaedic Surgery, College of Medical Evangelists, Loma Linda, CA, 1946-1955.


Attending Orthopaedic Surgeon, variously: Riverside Community Hospital, Riverside General Hospital, Parkview Community Hospital, Experanza Inter-community Hospital, Good Samaritan Hospital (now-Midwood Community Hospital), Stanton, CA, 90680.

Founder and Medical Director, variously: Angel View Crippled Childrens Foundation, Desert Crippled Childrens Clinic; now -- Desert Arthritis Medical Clinic, Desert Hot Springs, CA 92240.

Certified by the American Board of Orthopaedic Surgery, Fellow of the American College of Surgeons, Fellow of the American Academy of Orthopaedic Surgery, Fellow of the International College of Applied Nutrition, Member of the American Medical Association, the California Medical Association, the Orange County Medical Association and the Pan-Pacific Surgical Association.

Chairman of the Medical and Scientific Advisory Board of the Rheumatoid Disease Foundation.

Editor of Arthritis and Health News. Editor and Publisher of Fight Back Against Arthritis. Desert Arthritis Medical Center, Inc. 13-630 Mountain View Road, Desert Hot Springs, CA 92240, USA.

Partially funded by this foundation, Robert Bingham, M.D. flew to Australia to attend the XVth International Congress of Rheumatology. Despite his respective extensive background in treating the crippled, he was shunted aside, ignored, and viewed as an interloper with no legitimate business at this professional gathering. Nonetheless Dr. Bingham persisted in presenting materials to all who would accept them.

It was at this same conference where world-wide rheumatologists voted to reverse the standard treatment regimen. Instead of progressing from the least damaging drug, i.e. aspirin, to the most damaging, methotrexate, these august personages decided to start rheumatoid victims on methotrexate and then to try to reduce dosages and drugs to finally end with the least damaging, aspirin.

Of course this procedure, now accepted by most rheumatologists, simply doesn’t work. No matter which damaging drug is used, symptoms are being treated and not causes. And, of course, starting with the most damaging treatment adds on more damage to an already
Medical data is for informational purposes only. You should always consult your family physician, or one of our referral physicians prior to treatment.

raging inferno. We view this as a form of insanity! At best, it represents rheumatology, along with the field of psychiatry, as a field medical discipline.

References
2. Medical College of Virginia, VA, USA: Contract in progress.
4. The Rheumatoid Disease Foundation, Route 4, Box 137, Franklin, TN, USA 37064. (Now see http://www.arthritistrust.org)
5. Vanderbilt University Department of Molecular Biology, TN, USA: Work and contract in progress.
6. Bowman Gray School of Medicine, Winston Salem, N.C., USA: Work in progress.